1318 / 1840
Open issues
• Technical feasibility: challenging
- dose constraints? Normal tissues recovery?
- GTV-CTV expansion? Volumes?
• Recurrent SCCHN: heterogeneous group
- HPV positive
- HPV negative
- SPT’s
• Integration with CT
- what drugs? Sequential or concurrent
schedule? Maintenance?